---
title: "RNR: Strong Q2 2026 results: $654.2M net income, 24% ROE, and robust capital returns"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293519145.md"
description: "Q2 2026 saw strong profitability with net income of $654.2M, a 24.0% ROE, and a 5.7% increase in book value per share. Underwriting, fee, and investment income all contributed, while disciplined capital management included $350M in share repurchases.Original document: RenaissanceRe Holdings Ltd. [RNR] SEC 8-K Current Report — Jul. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-22T20:39:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293519145.md)
  - [en](https://longbridge.com/en/news/293519145.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293519145.md)
generator: "portal-rs"
---

# RNR: Strong Q2 2026 results: $654.2M net income, 24% ROE, and robust capital returns

Q2 2026 saw strong profitability with net income of $654.2M, a 24.0% ROE, and a 5.7% increase in book value per share. Underwriting, fee, and investment income all contributed, while disciplined capital management included $350M in share repurchases.

Original document: RenaissanceRe Holdings Ltd. \[RNR\] SEC 8-K Current Report — Jul. 23 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [RNR.US](https://longbridge.com/en/quote/RNR.US.md)
- [RNR-F.US](https://longbridge.com/en/quote/RNR-F.US.md)

## Related News & Research

- [RenaissanceRe EVP, Chief Portfolio Officer Curtis Ross sells 5,000 common shares for $1.63 million](https://longbridge.com/en/news/296141969.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [Upwork (UPWK) Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/296158870.md)
- [DE: 3Q 2026 saw sales and profit growth, but FY 2026 guidance signals industry headwinds](https://longbridge.com/en/news/296475895.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**